TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07435649: Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Patients With Suspecte

Sponsor: Delve Bio, Inc. · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 400 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$9,408,000

Rescue Site Savings

+$6,203,400

Unlock Full NCT07435649 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07435649 Rescue Dossier →